company background image
CERT logo

Certara NasdaqGS:CERT Stock Report

Last Price

US$17.62

Market Cap

US$2.8b

7D

-0.2%

1Y

-26.2%

Updated

27 Mar, 2024

Data

Company Financials +

CERT Stock Overview

Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally.

CERT fundamental analysis
Snowflake Score
Valuation2/6
Future Growth4/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Rewards

Risk Analysis

No risks detected for CERT from our risk checks.

Certara, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Certara
Historical stock prices
Current Share PriceUS$17.62
52 Week HighUS$24.96
52 Week LowUS$11.81
Beta1.62
1 Month Change4.51%
3 Month Change-1.56%
1 Year Change-26.15%
3 Year Change-35.46%
5 Year Changen/a
Change since IPO-53.73%

Recent News & Updates

Certara, Inc.'s (NASDAQ:CERT) Share Price Could Signal Some Risk

Mar 21
Certara, Inc.'s (NASDAQ:CERT) Share Price Could Signal Some Risk

Returns Are Gaining Momentum At Certara (NASDAQ:CERT)

Feb 17
Returns Are Gaining Momentum At Certara (NASDAQ:CERT)

Recent updates

Certara, Inc.'s (NASDAQ:CERT) Share Price Could Signal Some Risk

Mar 21
Certara, Inc.'s (NASDAQ:CERT) Share Price Could Signal Some Risk

Returns Are Gaining Momentum At Certara (NASDAQ:CERT)

Feb 17
Returns Are Gaining Momentum At Certara (NASDAQ:CERT)

Certara: Applied BioMath Acquisition And Simcyp Launch Should Drive Growth

Jan 30

Calculating The Fair Value Of Certara, Inc. (NASDAQ:CERT)

Dec 07
Calculating The Fair Value Of Certara, Inc. (NASDAQ:CERT)

Risks To Shareholder Returns Are Elevated At These Prices For Certara, Inc. (NASDAQ:CERT)

Oct 31
Risks To Shareholder Returns Are Elevated At These Prices For Certara, Inc. (NASDAQ:CERT)

Is It Time To Consider Buying Certara, Inc. (NASDAQ:CERT)?

Sep 17
Is It Time To Consider Buying Certara, Inc. (NASDAQ:CERT)?

An Intrinsic Calculation For Certara, Inc. (NASDAQ:CERT) Suggests It's 29% Undervalued

Aug 30
An Intrinsic Calculation For Certara, Inc. (NASDAQ:CERT) Suggests It's 29% Undervalued

Certara (NASDAQ:CERT) Shareholders Will Want The ROCE Trajectory To Continue

Aug 03
Certara (NASDAQ:CERT) Shareholders Will Want The ROCE Trajectory To Continue

Certara: A Story To Watch

Sep 27

Certara to raise capital in secondary stock offering

Aug 12

Certara Looks Positioned For Increased Growth In 2022

Feb 02

Certara: Global Biosimulation Firm Positions Itself For Stability Into The Long Term

Sep 29

Shareholder Returns

CERTUS Healthcare ServicesUS Market
7D-0.2%0.04%0.4%
1Y-26.2%5.7%28.8%

Return vs Industry: CERT underperformed the US Healthcare Services industry which returned 5.8% over the past year.

Return vs Market: CERT underperformed the US Market which returned 29.5% over the past year.

Price Volatility

Is CERT's price volatile compared to industry and market?
CERT volatility
CERT Average Weekly Movement5.5%
Healthcare Services Industry Average Movement10.8%
Market Average Movement6.0%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.0%

Stable Share Price: CERT has not had significant price volatility in the past 3 months.

Volatility Over Time: CERT's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
20081,365Bill Feeheryhttps://www.certara.com

Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics. The company provides Simcyp Simulator, a mechanistic biosimulation platform mechanistic biosimulation investigational new drug and translational stages; Simcyp Biopharmaceutics, used to identify and refine drug formulations; and Simcyp Secondary Intelligence which integrates toxicology with quantitative analysis of networks of molecular and functional biological changes to identify drug toxicity and adverse drug reactions.

Certara, Inc. Fundamentals Summary

How do Certara's earnings and revenue compare to its market cap?
CERT fundamental statistics
Market capUS$2.82b
Earnings (TTM)-US$55.36m
Revenue (TTM)US$354.34m

7.9x

P/S Ratio

-50.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CERT income statement (TTM)
RevenueUS$354.34m
Cost of RevenueUS$141.02m
Gross ProfitUS$213.32m
Other ExpensesUS$268.67m
Earnings-US$55.36m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.35
Gross Margin60.20%
Net Profit Margin-15.62%
Debt/Equity Ratio27.8%

How did CERT perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.